New drug PT0511 targets Hard-to-Treat KRAS cancers in early trial
NCT ID NCT07300150
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing a new drug called PT0511, given alone or with cetuximab, in adults with advanced solid tumors that have a KRAS mutation or amplification. The main goals are to check safety, find the best dose, and see how the body handles the drug. About 195 participants with colorectal, pancreatic, lung, or other solid tumors will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PT0511 (intravenous infusion) and cetuximab (intravenous infusion)
What this could lead to
If successful, this could point toward a new treatment option for advanced cancers with KRAS mutations, such as colorectal, pancreatic, or lung cancer.
What could go wrong
This is an early Phase 1 trial focused on safety and dosing, so it is too soon to know if PT0511 will work. Side effects and lack of efficacy are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dana-Farber/Massachusetts General Hospital, Inc
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Email: •••••@•••••
-
NEXT Virginia
RECRUITINGFairfax, Virginia, 22031, United States
Contact Email: •••••@•••••
-
New Experimental Therapeutics of San Antonio LLC
RECRUITINGSan Antonio, Texas, 78229, United States
Contact Email: •••••@•••••
-
START - South Texas Accelerated Research Therapeutics, LLC
RECRUITINGSan Antonio, Texas, 78229, United States
Contact Email: •••••@•••••
-
START Mountain Region
RECRUITINGWest Valley City, Utah, 84119, United States
Contact Email: •••••@•••••